Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Karuna Therapeutics cut by analysts following news of Bristol-Myers Squibb acquisition
December 26, 2023 11:14 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) was downgraded by analysts at Leerink Partners, H.C. Wainwright and Maxim Group on Tuesday following news that the company will be acquired by Bristol-Myers Squibb (NYSE: BMY)for a total value of... More
Bristol-Myers Squibb (BMY) to buy RayzeBio (RYZB) for $4.1 billion
December 26, 2023 7:56 AM ESTPharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) announced Tuesday that it is acquiring RayzeBio (NASDAQ: RYZB) for $4.1 billion, strengthening its oncology portfolio with promising radiopharmaceutical therapeutics (RPTs).
The deal, valued at $62.50 per RayzeBio share, was... More
RayzeBio (RYZB) to Resume Trading at 7:30 a.m.
December 26, 2023 7:05 AM ESTRayzeBio (NASDAQ: RYZB) to Resume Trading at 7:30 a.m.
Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb... More